Dr. Roy Alcalay, MD

• Neurology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Tel Aviv University School Of Medicine

  Medical School, 2009

• Massachusetts General Hospital

  Residency Hospital, 2007

• Interest in Genetic Testing in Ashkenazi Jewish Parkinson's Disease Patients and Their Unaffected Relatives, 2014-08-17

• Prevalence and Features of Unreported Dystonia in a Family Study of "Pure” Essential Tremor, 2012-10-23

• Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America, 2021-04-12

• LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease, 2022-07-19

• Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism, 2020-09-10

• Lipid level alteration in human and cellular models of alpha synuclein mutations, 2022-04-25

• Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures, 2022-03-21

• WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes, 2022-06-09

• Widespread tau-specific CD4 T cell reactivity in the general population, 2019-05-13

• Genetic Testing for Parkinson's Disease: Current Practice, Knowledge and Attitudes among US and Canadian Movement Disorders Specialists, 2019-11-04

• Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson's Disease Project, 2023-10-03

• SMPD1mutations, activity and a-synuclein accumulation in Parkinson's disease, 2019-02-20

• Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson's disease, 2023-05-10

• Non-motor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in theLRRK2gene, 2015-03-21

• Unaltered T cell responses to common antigens in individuals with Parkinson's disease, 2022-11-25

• Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts, 2022-06-08

• Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders, 2020-04-16

• Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson's Disease?, 2021-10-26

• Evidence for increased completed suicide in first-degree relatives ofLRRK2G2019S mutation Parkinson's disease, 2018-11-08

• Estimation of Genetic Risk Function with Covariates in the Presence of Missing Genotypes, 2017-06-27

• Parkinson's disease with Lewy bodies associated with a heterozygousPARKINdosage mutation, 2013-12-27

• Plasma Metabolite Signature Classifies Male LRRK2 Parkinson's Disease Patients, 2022-02-05

• The impact of COVID-19 and social distancing on people with Parkinson's disease: a survey study, 2021-01-21

• Longitudinal clinical and biomarker characteristics of non-manifestingLRRK2G2019S carriers in the PPMI cohort, 2022-10-22

• Lipidomics prediction of Parkinson's disease severity: A machine-learning analysis, 2021-03-09

• Clinical and pathological characteristics ofLRRK2G2019S patients with PD, 2011-12-23

• Cancer Outcomes Among Parkinson's Disease Patients with Leucine Rich Repeat Kinase 2 Mutations, Idiopathic Parkinson's Disease Patients, and Nonaffected Controls, 2019-07-26

• Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson's disease and multiple system atrophy, 2023-03-20

• Essential Tremor-Parkinson's Disease: A Double Whammy, 2016-04-23

• Tools for communicating risk for Parkinson's disease, 2022-11-29

• Urinary proteome profiling for stratifying patients with familial Parkinson's disease, 2021-01-22